Videos
The Drugs and Devices Australia Webinar 2022.
Hosted by our Partner & Director George Papadopoulos and Sarah Griffin Director of MedTechnique Consulting, sharing their insights into the complex world of drug and device reimbursement applications and strategy in the Australian market. George and Sarah discuss the latest developments in gaining reimbursement in the Australian market, wrap up the year 2022 and answer webinar attendee’s questions.
The Drugs and Devices Australia Webinar 2021.
Hosted by our Partner & Director George Papadopoulos and Sarah Griffin Director of MedTechnique Consulting, sharing their insights into the complex world of drug and device reimbursement applications and strategy in the Australian market. George and Sarah discuss the latest developments in gaining reimbursement in the Australian market, wrap up the year 2021 and answer webinar attendee’s questions.
Digital Health & Industry virtual panel discussion, hosted by the University of Sydney, 2021.
On Wednesday 21 July, 2021, our Director, George Papadopoulos participated as a panellist in the Digital Health & Industry virtual panel discussion, hosted by the University of Sydney, Digital Health ECR Community and co-ordinated by Audrey Rollin.
With the following panellists, Associate Professor Andrew Campbell of the University of Sydney, Dr David Hansen CEO of CSIRO’s Australian e-Health Research Centre, Ms Michelle Gallaher CEO of Opyl, Natasa Lazaveric , PhD candidate in health science and physics at the University of Sydney and Arthur Brandwood, Director at ARCS Australia and George Papadopoulos, Director of Lucid Health Consulting.
The following key insights were shared during the live panel webinar discussion:
How to engage with industry and its critical role in digital health research translation;
How to bring research to market, where and when to look for funding opportunities, and how to connect with industry professionals;
The different pathways from academia to industry.
The Digital Health ECR used the Padlet discussion format to interact collaboratively live during the webinar and a copy of this discussion is available here: Digital Health ECR Industry Webinar Padlet PDF
6th Annual Drugs & Devices Australia – Reimbursement Update, 2020.
Hosted by our Partner & Director George Papadopoulos and Sarah Griffin Director of MedTechnique Consulting, sharing their insights into the complex world of drug and device reimbursement applications and strategy in the Australian market. Sarah and George discuss the latest developments in gaining reimbursement in the Australian market.
The 5th Annual Drugs & Devices Australia Webinar – Reimbursement Update.
Learn the latest developments in gaining reimbursement in the Australian market and an overview of 2019 by viewing the Fifth Annual Drugs & Devices Australia, Webinar – Reimbursement Australia, 2019. Hosted by our Director George Papadopoulos and Sarah Griffin, Director of MedTechnique Consulting.
George and Sarah share their insights into the complex world of drug and device reimbursement applications and strategy in the Australian market: as well as answering webinar attendee’s questions.
Real world evidence: how is it being used in Australian pharmaceutical listings?
Watch an interview with Lucid Health Consulting’s Director and Chairman of ARCs Australia, George Papadopoulos and his guests, Professor Wilson, Director and Professor at Menzies Centre for Health Policy and Chair PBAC and Brittany Schoeninger, Associate Principle, IQVIA, as part of the ARCS Talks, during the ARCS Annual Conference, 2019.
The interview examines the evolving role of Real World Evidence in Australia – including how supply of and demand for RWE are changing locally – as well as explore how effective cross-functional evidence planning can help you translate Real World Data to Real World patient benefit.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.